Telitacicept wins NMPA conditional approval for IgA nephropathy
Vor Bio and its Chinese collaborator RemeGen have secured conditional approval from China's National Medical Products Administration (NMPA) for telitacicept in adult patients with IgA nephropathy (IgAN), making it the first BAFF/APRIL-targeting therapy to receive regulatory clearance in the indication.
The decision, announced on 8 June 2026, rests on data from RemeGen's completed Phase 2 study and the Phase 3 TELIGAN trial, Part A results of which were published earlier this year in The New England Journal of Medicine. In the primary analysis, patients receiving telitacicept 240 mg achieved a 59% reduction in urinary protein-to-creatinine ratio (UPCR) from baseline at week 39, equating to a 55% placebo-adjusted reduction. Estimated glomerular filtration rate remained broadly stable in the treated arm over the same period, while the placebo group showed greater renal function decline. The study also recorded reductions in circulating CD19+ B cells and serum immunoglobulin levels consistent with the drug's mechanism.
The therapy and its mechanism
Telitacicept is a recombinant fusion protein that inhibits both BLyS (BAFF) and APRIL, two cytokines central to B-cell and plasma-cell survival. In IgAN, the prevailing pathogenic model holds that overproduction of galactose-deficient IgA1 — driven partly by BAFF and APRIL — triggers immune-complex deposition in the glomeruli, leading to inflammation and progressive renal injury. Up to 40% of IgAN patients progress to end-stage renal disease within 20 years of diagnosis, and current standard-of-care therapies — renin-angiotensin system blockade, blood pressure optimisation, and SGLT2 inhibitors — manage progression rather than the underlying immunopathology.
Jean-Paul Kress, chief executive and chairman of Vor Bio, described the approval as validating "the potential of dual BAFF/APRIL inhibition to address the underlying immunopathology of IgAN" and expressed confidence that telitacicept could become "a foundational therapy across multiple autoimmune diseases globally."
IgAN is the fourth approved indication for telitacicept in China, joining systemic lupus erythematosus, rheumatoid arthritis, and generalised myasthenia gravis (gMG). Under the collaboration structure, RemeGen retains development, regulatory, and commercial rights in Greater China; Vor Bio holds exclusive rights for the rest of the world.
Market context and competitive landscape
IgAN has become one of the more competitive nephrology sub-sectors in recent years. Calliditas Therapeutics' targeted-release budesonide formulation (Nefecon/Tarpeyo) was approved by the FDA and EMA for the indication, while Travere Therapeutics' sparsentan — a dual endothelin/angiotensin receptor antagonist — received full FDA approval in 2024 after an accelerated pathway. Both compounds address proteinuria as a surrogate endpoint but act through different mechanisms. The conditional nature of the NMPA approval for telitacicept indicates that RemeGen will be required to provide additional confirmatory data, likely longer-term renal outcomes, before full approval is granted.
For Vor Bio's ex-China ambitions, the NEJM publication and NMPA clearance provide meaningful clinical validation ahead of regulatory interactions in the United States, Europe, and Japan. The company is currently running global Phase 3 trials in gMG and Sjögren's disease (SjD), with IgAN potentially representing an additional registration pathway. The dual-target mechanism differentiates telitacicept from single-target BAFF inhibitors such as belimumab, which is already approved in lupus nephritis and SLE — a positioning argument Vor Bio will need to substantiate with comparative or longer-term outcomes data as the global programme matures.